FeaturedNews LUMC & Batavia Biosciences Burst the Bubble Severe Combined Immunodeficiency (SCID) disease affects 1 in 35,000 newborns annually, of which approximately 145…Aaron Ogdahl29 November 2022
BlogFeaturedViral vaccinesViral vectors Driving down COGs of viral vector-based biopharmaceuticals How do you keep cost of goods (COGs) for viral vector-based medicines within reason to…Aaron Ogdahl8 November 2022
FeaturedNews Batavia enters the commercial manufacturing business Leiden, The Netherlands, June 28, 2022 – Today, Batavia Biosciences announces that it will extend…Aaron Ogdahl28 June 2022
FeaturedScientific publication Adenoviral vectors for cardiovascular gene therapy applications: a clinical and industry perspective Adenoviruses are being explored as vectors for cardiovascular gene therapy purposes against many heritable diseases.…Aaron Ogdahl26 May 2022
BlogFeaturedViral vaccinesViral vectors Taking your adenoviral vector product from R&D to the clinic Adenoviruses have been shown to be very effective vehicles for delivering genetic material to cells…Claire Otjes25 April 2022
FeaturedNews Batavia wins 2022 ViE Award for Best Process Development Washington, April 20, 2022 - Batavia Biosciences was honored this week during the Vaccine Industry…Claire Otjes20 April 2022
BlogFeaturedViral vaccinesViral vectors Adenovirus vectors: cutting edge delivery vehicles for gene therapy and vaccine development Adenovirus (Ad) vectors are used to develop gene therapy products and vaccines. Decades of research…Aaron Ogdahl11 April 2022
BlogFeaturedViral vaccinesViral vectors Adenoviral vector platform: past and current challenges Adenoviruses have been explored for gene therapy purposes for many decades. They are DNA viruses,…Aaron Ogdahl24 March 2022